Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02927912 · ClinicalTrials.gov registry record · Phase 2
Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction
A Phase 2 study of Stage IIA Breast Cancer and Stage IIB Breast Cancer, sponsored by Ohio State University Comprehensive Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
- 5
- Study locations
NCT02927912 is a Phase 2 study of Stage IIA Breast Cancer and Stage IIB Breast Cancer that is active but no longer recruiting, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 108 participants, below the 252-participant average among 17 other Stage IIA Breast Cancer trials with a reported enrollment target (57% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT02927912, a Phase 2 study of Stage IIA Breast Cancer and Stage IIB Breast Cancer, is active but no longer recruiting, sponsored by Ohio State University Comprehensive Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
- 5
- Study locations
Study Summary
This phase II trial studies the side effects of intraoperative electron beam radiotherapy boost and to see how well it works in treating patients with stage I-II breast cancer undergoing surgery with reconstruction. Giving a single dose of electron beam radiation to the tumor cavity during the breast surgery before reconstruction may be a better way to kill tumor cells and shrink tumors.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- RADIATION Radiation Therapy
- PROCEDURE Lumpectomy
- RADIATION Electron Beam Therapy
Study Locations (5)
Ohio
- University Hospitals - Cleveland
- Ohio State University Comprehensive Cancer Center - Columbus
North Carolina
- University of North Carolina - Chapel Hill
South Dakota
- Avera Cancer Institute - Sioux Falls
Montreal
- Centre Hospitalier de I'Universite de Montreal - Québec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2017-10-16 |
| Est. Completion | 2026-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02927912
The ClinicalTrials.gov registry entry for NCT02927912 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 252-participant average among 17 other Stage IIA Breast Cancer trials with a reported enrollment target (57% lower). The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Stage IIA Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Quality-of-Life Assessment is the first listed.
NCT02927912 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Ohio, North Carolina, South Dakota.
Frequently Asked Questions
What is clinical trial NCT02927912 about?
NCT02927912 is a clinical study titled "Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction". This phase II trial studies the side effects of intraoperative electron beam radiotherapy boost and to see how well it works in treating patients with stage I-II breast cancer undergoing surgery with reconstruction. Giving a single dose of electron beam radiation to the tumor cavity during the breas...
What is the current status of trial NCT02927912?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2017-10-16. Estimated completion is 2026-11-30.
What conditions does trial NCT02927912 study?
This clinical trial studies the following conditions: Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer.
What interventions are being tested in trial NCT02927912?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Radiation Therapy (RADIATION), Lumpectomy (PROCEDURE), Electron Beam Therapy (RADIATION).
Who is sponsoring clinical trial NCT02927912?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02927912 being conducted?
This trial has 5 study locations across North Carolina, Ohio, South Dakota, Montreal. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IIA Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
RECRUITING · Phase 2
-
Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
ACTIVE NOT RECRUITING · Phase 2
-
Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.